Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARRY 8.05 -0.15 (-1.83%)
price chart
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma ...
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), ...
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after announcing a pipeline acquisition from ...
Firm Rating Update on Array Biopharma Inc  Stafford Daily
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference  MarketWatch
Update: Array BioPharma Inc. Short Interest Grows by 19.5%
Array BioPharma Inc. (NASDAQ:ARRY) reported a rise of 19.5% or 3,870,322 shares in its short interest. The short figure came in at 18.3% of the total floats.
Share Price of Array BioPharma Inc. Drops by -3.4%  Ashburn Daily
Closing Bell Reports: First Solar, Inc. (FSLR), Array BioPharma, Inc. (ARRY ...  WallStreet Scope
Array Biopharma Inc Analyst Rating Update
As many as 7 brokerage firms have rated Array Biopharma Inc (NASDAQ:ARRY) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of Neutral.
Array Biopharma Given Consensus Recommendation of "Buy" by ...  Mideast Time
Hottest Healthcare Stocks Now � ZIOP ARRY NLNK LGND
Ziopharm Oncology Inc (ZIOP): ZIOP stock is up 6.7% today and up 24.3% in the last month. Array Biopharma Inc (ARRY): ARRY stock is up 4.5% today.
Zacks Long Term Rating Update on Array Biopharma Inc
Array Biopharma Inc (NASDAQ:ARRY) remains a strong buy in the latest set of rankings. The counter has received an average rating of 1 by 7 analysts.
Brokerage Firm Rating Disclosure Update on Array Biopharma Inc
Jefferies maintains their rating on the shares of Array Biopharma Inc (NASDAQ:ARRY). The current rating of the shares is Buy.
Tuesday Stocks to Watch: Array Biopharma Inc , Lowes Companies Inc , Yum ...  Ashburn Daily
Company Shares of Array Biopharma Inc Rally 4.61%  Winston View
Company Shares of Array Biopharma Inc Rally 2.36%
Shares of Array Biopharma Inc (NASDAQ:ARRY) rose by 2.36% in the past week and 15.89% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 1.72% and the outperformance increases to 12.68% for the last 4 weeks.
Brokerages Set Array Biopharma Price Target at $9.60 (NASDAQ:ARRY)  The Legacy
Morning Buzz: Array BioPharma, Inc. (ARRY), Broadcom Corp. (BRCM), TOTAL ...  WallStreet Scope
CFO Moves: Visa, Array BioPharma, Epizyme
Array BioPharma Inc.ARRY -1.85%, a Boulder, Colo.-based biopharmaceutical company, named Dave Horin interim CFO. Mr. Horin is a managing partner with Chord Advisors LLC, according to a regulatory filing.
Array BioPharma Inc. (NASDAQ:ARRY) Update: Array BioPharma appoints ...
Array BioPharma Inc. (NASDAQ:ARRY) Updated based on the information released on Monday, Mar 2nd, Array BioPharma appoints Andrew Robbins to COO.
Morning Trending Tickers: JinkoSolar Holding Co., Ltd. (JKS), Array ...  WallStreet Scope
Aggressive Stocks: Extreme Networks Inc. (NASDAQ:EXTR), Array BioPharma ...  eMarketsDaily